🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
PDS Biotechnology Corporation (PDSB)
NASDAQ: PDSB · Real-Time Price · USD
0.8073
+0.0232 (2.96%)
At close: Nov 19, 2026, 4:00 PM EST
0.8200
+0.0127 (1.57%)
After-hours: Nov 19, 2026, 7:50 PM EST

Company Description

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States.

The company’s lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.

It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers.

In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment.

It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, Georgia Research Foundation, and MSD International GmbH.

PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.

PDS Biotechnology Corporation
PDS Biotechnology logo
CountryUnited States
Founded2005
IndustryBiotechnology
SectorHealthcare
Employees21
CEOFrank Bedu-Addo

Contact Details

Address:
303A College Road East
Princeton, New Jersey 08540
United States
Phone800 208 3343
Websitepdsbiotech.com

Stock Details

Ticker SymbolPDSB
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code1472091
CUSIP Number70465T107
ISIN NumberUS70465T1079
Employer ID26-4231384
SIC Code2834

Key Executives

NamePosition
Dr. Frank K. Bedu-Addo Ph.D.Founder, President, Chief Executive Officer, Interim Chief Financial Officer and Director
Dr. Kirk V. Shepard M.D.Chief Medical Officer
Janetta TrochimiukController and Interim Principal Accounting Officer
Dr. Gregory L. Conn Ph.D.Chief Scientific Officer
Spencer Brown J.D.Senior Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer

Latest SEC Filings

DateTypeTitle
Nov 17, 20264Statement of changes in beneficial ownership of securities
Nov 16, 202610-QQuarterly Report
Nov 13, 20268-KCurrent Report
Nov 12, 2026SCHEDULE 13D/AFiling
Nov 10, 20268-KCurrent Report
Oct 21, 20268-KCurrent Report
Oct 20, 20268-KCurrent Report
Oct 14, 2026S-3Registration statement under Securities Act of 1933
Oct 6, 20268-KCurrent Report
Sep 22, 20268-KCurrent Report
Investor Relations Documents
Annual and quarterly reports, earnings releases, and presentation slides